(Q39725130)

English

Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells

scientific article published on 22 March 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells (English)

1 reference

Europe PubMed Central

14 September 2017

phosphorylation

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

14 September 2017

author name string

M P Albero

1

1 reference

Europe PubMed Central

14 September 2017

J M Vaquer

2

1 reference

Europe PubMed Central

14 September 2017

E J Andreu

3

1 reference

Europe PubMed Central

14 September 2017

J J Villanueva

4

1 reference

Europe PubMed Central

14 September 2017

L Franch

5

1 reference

Europe PubMed Central

14 September 2017

C Ivorra

6

1 reference

Europe PubMed Central

14 September 2017

E Poch

7

1 reference

Europe PubMed Central

14 September 2017

X Agirre

8

1 reference

Europe PubMed Central

14 September 2017

I Pérez-Roger

10

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

22 March 2010

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

29

1 reference

Europe PubMed Central

14 September 2017

22

1 reference

Europe PubMed Central

14 September 2017

3276-3286

1 reference

Europe PubMed Central

14 September 2017

https://scigraph.springernature.com/pub.10.1038/onc.2010.81

0 references

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

21 January 2018

Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

21 January 2018

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

A cell cycle regulatory network controlling NF-kappaB subunit activity and function

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Targeting the UPS as therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome proteolytic profile is linked to Bcr-Abl expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The generation of nfkb2 p52: mechanism and efficiency

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome inhibitor drugs on the rise

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

RB, the conductor that orchestrates life, death and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Skp2-dependent degradation of p27kip1 is essential for cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Recycling the Cell Cycle

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Two pathways to NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Therapy options in imatinib failures

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The role of myc in transformation by BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Living with or without cyclins and cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome inhibition as novel treatment strategy in leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib: putting mantle cell lymphoma on death row.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Identifiers

10.1038/ONC.2010.81

1 reference

Europe PubMed Central

14 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39725130&oldid=2089157835"